Endoscopic surveillance of Barrett’s esophagus (BE), aiming to detect prevalent dysplasia and adenocarcinoma, followed by effective endoscopic treatment, is an integral part of the esophageal adenocarcinoma (EAC) prevention paradigm. However, several limitations such as the subtle appearance of dysplasia, sampling error (inherent in current surveillance protocols), and non-compliance with surveillance recommendations, lead to missed dysplasia and neoplasia, reducing the effectiveness of surveillance as currently practiced.